CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (USD $) In Thousands, except Share data	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Laboratory services:
Drugs-of-abuse testing services	$ 10,806	$ 10,160	$ 20,446	$ 18,956
Clinical & other laboratory services	9,133	7,578	17,108	14,468
Clinical trial services	2,323	2,037	4,859	2,870
Product sales	5,659	5,410	11,244	10,052
Total revenues	27,921	25,185	53,657	46,346
COST OF REVENUES:
Cost of services	13,623	12,551	26,575	23,584
Cost of sales	2,222	2,293	4,555	4,321
Total cost of revenues	15,845	14,844	31,130	27,905
GROSS PROFIT	12,076	10,341	22,527	18,441
OPERATING EXPENSES:
Selling, general and administrative	9,281	8,231	17,905	15,664
Research and development	622	573	1,216	1,122
Total operating expenses	9,903	8,804	19,121	16,786
INCOME FROM OPERATIONS	2,173	1,537	3,406	1,655
OTHER INCOME (EXPENSE):
Interest expense	(18)	0	(42)	(1)
Other income	57	56	73	61
Total other income (expense)	39	56	31	60
INCOME BEFORE INCOME TAX EXPENSE	2,212	1,593	3,437	1,715
INCOME TAX EXPENSE	(808)	(581)	(1,255)	(626)
NET INCOME	$ 1,404	$ 1,012	$ 2,182	$ 1,089
BASIC EARNINGS PER COMMON SHARE (in dollars per share)	$ 0.16	$ 0.12	$ 0.25	$ 0.13
DILUTED EARNINGS PER COMMON SHARE (in dollars per share)	$ 0.16	$ 0.11	$ 0.24	$ 0.12
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:
Basic (in shares)	8,847,870	8,700,838	8,849,042	8,669,326
Diluted (in shares)	9,052,714	8,963,870	9,048,185	8,907,773